Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence

International Journal of Urology

Volumn 10, Issue 4, 2003, Pages 183-189

  Irie, Akira ^a,b   Uchida, Toyoaki ^a   Yamashita, Hideyuki ^a   Matsumoto, Kazumasa ^a   Satoh, Takefumi ^a   Koh, Hideshige ^a   Shimura, Satoru ^a   Iwamura, Masatsugu ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Low dose; Prophylaxis; Tokyo 172 strain

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTHRITIS; ARTICLE; BACTERIAL STRAIN; BLADDER CANCER; BLADDER IRRITATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INSTILLATION; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATURIA; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TUBERCULOSIS; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 0038485672     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0919-8172.2003.00607.x     Document Type: Article

References (22)

1. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: Is it effective? J. Urol. 1991; 146: 32-5.
2. Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J. Urol. 1992; 147: 1256-8.
3. Mack D, Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guérin therapy in high-risk superficial bladder cancer. Urology 1995; 45: 958-61.
4. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer. Int. Urol. Nephrol. 1995; 27: 723-33.
5. Martinez-Pineiro JA, Solsona E, Flores N, Isorna S. Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur. Urol. 1995; 27: 13-8.
6. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J. Urol. 1996; 156: 1602-5.
7. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success. Eur. Urol. 1998; 34: 67-72.
8. Lebret T, Bohin D, Kassardjian Z et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. J. Urol. 2000; 163: 63-7.
9. Mack D, Holtl W, Bassi P et al. The ablative effect of quarter dose bacillus Calmette-Guérin on a papillary marker lesion of the bladder. J. Urol. 2001; 165: 401-3.
10. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J. Urol. 1982; 128: 1104-8.
11. Kelley DR, Ratliff TL, Catalona WJ et al. Intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J. Urol. 1985; 134: 48-53.
12. Mukherjee A, Persad R, Smith PJ. Intravesical BCG treatment for superficial bladder cancer. Long-term results using two different strains of BCG. Br. J. Urol. 1992; 69: 147-50.
13. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Int. J. Urol. 1997; 4: 139-43.
14. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 1124-9.
15. Akaza H, Iwasaki A, Ohtani M et al. Expression of anti-tumor response: Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer 1993; 72: 558-63.
16. Loening S, Narayana A, Yoder L et al. Factors influencing the recurrence rate of bladder cancer. J. Urol. 1980; 123: 29-31.
17. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997; 49: 687-90.
18. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J. Urol. 2002; 167: 1573-83.
19. Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J. Urol. 1992; 148: 1413-9.
20. Mufti GR, Virdi JS, Singh M. 'Solitary' Ta-T1, G1 bladder tumour: History and long-term prognosis. Eur. Urol. 1990; 18: 101-6.
21. Lacombe L, Dalbagni G, Zhang ZF et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: Correlation to clinical outcome. J. Clin. Oncol. 1996; 14: 2646-52.
22. Lebret T, Bacette V, Barbagelatta M et al. Correlation between p53 overexpression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J. Urol. 1998; 159: 788-91.